key: cord-0901664-z7z852di authors: Tan, Jing Yuan; Tan, Chuen Wen; Wong, Wan Hui; Cheong, May Anne; Lee, Lai Heng; Kalimuddin, Shirin; Low, Jenny Guek Hong; Ng, Heng Joo title: Post‐hospitalization venous thromboembolism in COVID‐19 patients: Evidence against routine post‐hospitalization prophylactic anticoagulation date: 2021-06-19 journal: Int J Lab Hematol DOI: 10.1111/ijlh.13633 sha: 67b7489418d0d5e89a37cc69fda17c80a2e17137 doc_id: 901664 cord_uid: z7z852di nan The association between COVID-19 and an increased risk of venous thromboembolic (VTE) events, particularly in the critically ill, has been well reported. 1 While guidelines exist for thromboprophylaxis during hospitalization, the role for thromboprophylaxis post-hospitalization remains uncertain and controversial. Current guidelines recommend against the blanket use of post-hospitalization thromboprophylaxis and suggest that it be considered after individualized assessment of bleeding and thrombotic risk. 1, 2 There is however a paucity of data on the post-hospitalization VTE events in COVID-19. 3, 4 In the absence of prospective data, the role for prophylactic anticoagulation in COVID-19 patients post-hospitalization remains uncertain. In our prospective study, we had 2 objectives: (a) to study the incidence of VTE events post-discharge, which was determined by looking at readmissions to our hospital for VTE events or patientreported symptoms at follow-up that would suggest a VTE event and necessitate admission for further evaluation, (b) to characterize the thrombogenicity of recovered COVID-19 by studying hemostatic assays, specifically activated partial thromboplastin time (aPTT)-based clot waveform analysis (CWA). COVID-19 patients admitted to Singapore General Hospital were enrolled upon written informed consent. This study was approved by SingHealth Centralized Institutional Review board (CIRB no. 2018/3045). All patients were given a six-to eight-week follow-up upon discharge. We calculated the modified IMPROVE-VTE score for our cohort. The International Medical Prevention Registry on Venous thromboembolism (IMPROVE) VTE score is a predictive score designed to assess the risk of VTE in hospitalized medical patients. 5 It has been used as a possible criteria in ongoing trials to decide on the need for posthospitalization VTE prophylaxis in COVID-19 patients. 6 APTT-based CWA were generated during the analysis of the standard aPTT assay triggered with Dade Actin FSL reagent (Siemens Healthcare) and retrieved from CS2100i automated coagulation analyzers (Sysmex Corporation). CWA parameters of interest were min1, min2, and max2 denoting the maximum velocity, maximum acceleration, and maximum deceleration of the clot formation process, respectively. Higher parameters indicate hypercoagulability. 7 Coagulation samples for recovered COVID-19 patients were taken at 2 settings. In non-ICU patients, this was at follow-up; in ICU patients, when two consecutive COVID-19 testing were negative, indicating recovery. The coagulation profiles and CWA parameters were analyzed. Table 2 shows an independent comparison of coagulation profiles and CWA parameters of non-ICU COVID-19 patients during hospitalization and at follow-up. There was a significant decrease in median CWA parameters (min1 and min2) at follow-up (min1: 5.37%/s vs 4.37%/s, P = .013; min2: 0.79%/s 2 vs 0.69%/s 2 , P = .034) although their aPTT were not significantly different. At follow-up, all patients had CWA parameters and coagulation parameters within normal ranges. Among our study population, five patients had paired CWA results-during acute illness and at recovery. Of these, three patients exhibited elevated min1 during the acute phase of COVID-19, median (IQR) 7.31%/s (7.10,8.00), and the subsequent normalization of this parameter during recovery, median (IQR) 5.39%/s (5.06,5.68). Two of the three patients were ICU COVID-19 patients and were the only ICU patients in our study that had paired CWA parameters. We observed no VTE event during and post-hospitalization in our cohort. Studies reporting post-discharge VTE events in COVID-19 patients are few. In a retrospective study by Roberts et al, post-discharge VTE rate was 4.8 per 1000 discharges. 4 The authors concluded that the event rate was low and suggested against the use of post-discharge thromboprophylaxis. The majority of our patients were young to middle-aged with few comorbidities and had predominantly mild disease. In addition, the modified IMPROVE-VTE score was <4 in all our patients. The cutoffs used to select medically ill patients at high risk for VTE events and for the use of extended thromboprophylaxis were ≥4 or 2 or 3 with an elevated D-dimer. 5 While majority of patients did not have a D-dimer, in the non-ICU We acknowledge the extraordinary work of Singapore General Hospital clinical teams who work tirelessly in our emergency department, isolation wards, and acute respiratory infection wards. Our study could not have been done without their meticulous efforts in history taking and clinical documentation. The authors report no conflicts of interest. CWT and JYT had full access to all the data in the study and takes Review board (CIRB no. 2018/3045). The data used and analyzed in this study are available from the corresponding author on reasonable request. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review Postdischarge thrombosis and hemorrhage in patients with COVID-19 Postdischarge venous thromboembolism following hospital admission with COVID-19 Modified IMPROVE VTE risk score and elevated d-dimer identify a high venous thromboembolism risk in acutely Ill medical population for extended thromboprophylaxis COVID-19 discharge and follow-up recommendations Elevated activated partial thromboplastin time-based clot waveform analysis markers have strong positive association with acute venous thromboembolism Clinical and laboratory features of hypercoagulability in COVID-19 and other respiratory viral infections amongst predominantly younger adults with few comorbidities Analysis of coagulation parameters in patients with COVID-19 in Shanghai Post-hospitalization venous thromboembolism in COVID-19 patients: Evidence against routine post-hospitalization prophylactic anticoagulation